Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Viral resistance and genetic barrier of atazanavir].

Enfermedades infecciosas y microbiologia clinica - 1 Dec 2008

Mendoza Carmen De, Garrido Carolina, Treviño Ana, Anta Lourdes, Poveda Eva, Soriano Vicente

Abstract excerpt

Resistance to protease inhibitors (PI) is generally due to a mutation in the protease gene. Different changes have been described for each PI. The I 50L mutation is characteristic of resistance to atazanavir (ATV). It does not produce cross resistance to other PI; but it does increase susceptibility to all of them (hypersusceptibility). When PI are given concomitantly with low doses of ritonavir, the exposure to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Genes, pol
Share to HIV-2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Multicenter Studies as Topic

Share to Oligopeptides

Share to Ritonavir

Source

Identifiers

PMID: 20116614
DOI: 10.1016/S0213-005X(08)76617-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Viral resistance and genetic barrier of atazanavir].PMID 20116614Read ↗

Protease inhibitor resistance update: where are we now?Semantic proximity Read ↗

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).Semantic proximity Read ↗

[Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].Semantic proximity Read ↗

Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.Semantic proximity Read ↗

Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.Semantic proximity Read ↗

[Etravirine: genetic barrier and resistance development].Semantic proximity Read ↗

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.Semantic proximity Read ↗

Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.Semantic proximity Read ↗

[Telaprevir resistance].Semantic proximity Read ↗

Mechanisms of resistance to antiretroviral drugs--clinical implications.Semantic proximity Read ↗

Genetic Barriers to Resistance and Impact on Clinical ResponseSemantic proximity Read ↗

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.